Ciprofloxacin 0.3% ophthalmic solution — Competitive Intelligence Brief

Ciprofloxacin 0.3% ophthalmic solution (Ciprofloxacin 0.3% ophthalmic solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: fluoroquinolone antibiotic. Area: Ophthalmology.

phase 2 fluoroquinolone antibiotic DNA gyrase and topoisomerase IV Ophthalmology Small molecule

Target snapshot

Ciprofloxacin 0.3% ophthalmic solution (Ciprofloxacin 0.3% ophthalmic solution) — Allergan. Ciprofloxacin 0.3% ophthalmic solution works by inhibiting bacterial DNA gyrase and topoisomerase IV, which are essential for bacterial DNA replication and transcription.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ciprofloxacin 0.3% ophthalmic solution TARGET	Ciprofloxacin 0.3% ophthalmic solution	Allergan	phase 2	fluoroquinolone antibiotic	DNA gyrase and topoisomerase IV
Intracameral Moxifloxacin 0.1%	Intracameral Moxifloxacin 0.1%	Suzan A Rattan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Third generation fluoroquinolone	Third generation fluoroquinolone	University of Roma La Sapienza	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Gatifloxacin 0.3%	Gatifloxacin 0.3%	Innovative Medical	marketed	Fluoroquinolone	DNA gyrase and topoisomerase IV
moxifloxacin 0.5% eye drops	moxifloxacin 0.5% eye drops	Allergan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
levofloxacin-based triple therapy	levofloxacin-based triple therapy	National Taiwan University Hospital	marketed	Fluoroquinolone antibiotic (in combination therapy)	Bacterial DNA gyrase and topoisomerase IV
moxifloxacin 0.5% HCI ophthalmic solution	moxifloxacin 0.5% HCI ophthalmic solution	Allergan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (fluoroquinolone antibiotic class)

1. Allergan · 1 drug in this class
2. Shenzhen Third People's Hospital · 1 drug in this class
3. Sun Yat-sen University · 1 drug in this class
4. University of Rochester · 1 drug in this class